Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 841727 | 9.4 |
09:34 ET | 167944 | 9.47 |
09:36 ET | 197653 | 9.415 |
09:38 ET | 369132 | 9.45 |
09:39 ET | 321821 | 9.6565 |
09:41 ET | 405423 | 9.49 |
09:43 ET | 305502 | 9.5695 |
09:45 ET | 136103 | 9.5695 |
09:48 ET | 403021 | 9.825 |
09:50 ET | 671807 | 9.6476 |
09:52 ET | 298931 | 9.2398 |
09:54 ET | 261030 | 9.2704 |
09:56 ET | 432418 | 8.9532 |
09:57 ET | 271388 | 9.035 |
09:59 ET | 159618 | 8.97 |
10:01 ET | 115049 | 9.055 |
10:03 ET | 85984 | 9.1419 |
10:06 ET | 175689 | 9.3599 |
10:08 ET | 303928 | 9.395 |
10:10 ET | 182021 | 9.32 |
10:12 ET | 62257 | 9.42 |
10:14 ET | 162311 | 9.56 |
10:15 ET | 176641 | 9.7 |
10:17 ET | 144800 | 9.485 |
10:19 ET | 65337 | 9.51 |
10:21 ET | 86720 | 9.4597 |
10:24 ET | 58670 | 9.435 |
10:26 ET | 103288 | 9.4901 |
10:28 ET | 94293 | 9.3299 |
10:30 ET | 37508 | 9.39 |
10:32 ET | 78675 | 9.37 |
10:33 ET | 45351 | 9.38 |
10:35 ET | 43481 | 9.415 |
10:37 ET | 79172 | 9.4 |
10:39 ET | 50070 | 9.37 |
10:42 ET | 67922 | 9.4337 |
10:44 ET | 28713 | 9.3988 |
10:46 ET | 45300 | 9.4397 |
10:48 ET | 82393 | 9.26 |
10:50 ET | 41744 | 9.38 |
10:51 ET | 35440 | 9.265 |
10:53 ET | 339295 | 9.3599 |
10:55 ET | 23396 | 9.33 |
10:57 ET | 132437 | 9.375 |
11:00 ET | 60793 | 9.395 |
11:02 ET | 75623 | 9.3947 |
11:04 ET | 44529 | 9.335 |
11:06 ET | 28662 | 9.39 |
11:08 ET | 18344 | 9.385 |
11:09 ET | 21500 | 9.49 |
11:11 ET | 52969 | 9.48 |
11:13 ET | 20858 | 9.4401 |
11:15 ET | 100073 | 9.53 |
11:18 ET | 77242 | 9.3701 |
11:20 ET | 89150 | 9.465 |
11:22 ET | 21822 | 9.49 |
11:24 ET | 17342 | 9.505 |
11:26 ET | 89411 | 9.5 |
11:27 ET | 28199 | 9.455 |
11:29 ET | 25114 | 9.405 |
11:31 ET | 39994 | 9.41 |
11:33 ET | 12332 | 9.405 |
11:36 ET | 77814 | 9.375 |
11:38 ET | 31468 | 9.4372 |
11:40 ET | 12872 | 9.365 |
11:42 ET | 54946 | 9.335 |
11:44 ET | 46363 | 9.375 |
11:45 ET | 39707 | 9.355 |
11:47 ET | 40338 | 9.39 |
11:49 ET | 20445 | 9.435 |
11:51 ET | 14015 | 9.45 |
11:54 ET | 77428 | 9.5699 |
11:56 ET | 165816 | 9.63 |
11:58 ET | 98006 | 9.7201 |
12:00 ET | 54200 | 9.7704 |
12:02 ET | 108535 | 9.679 |
12:03 ET | 167661 | 9.8 |
12:05 ET | 100550 | 9.7381 |
12:07 ET | 72776 | 9.655 |
12:09 ET | 82969 | 9.415 |
12:12 ET | 65828 | 9.475 |
12:14 ET | 51978 | 9.425 |
12:16 ET | 63866 | 9.525 |
12:18 ET | 18035 | 9.56 |
12:20 ET | 62885 | 9.6 |
12:21 ET | 44297 | 9.595 |
12:23 ET | 29621 | 9.555 |
12:25 ET | 23815 | 9.56 |
12:27 ET | 21334 | 9.535 |
12:30 ET | 15573 | 9.5606 |
12:32 ET | 15057 | 9.55 |
12:34 ET | 22174 | 9.565 |
12:36 ET | 10166 | 9.555 |
12:38 ET | 19525 | 9.555 |
12:39 ET | 49041 | 9.51 |
12:41 ET | 34164 | 9.546 |
12:43 ET | 18902 | 9.525 |
12:45 ET | 63458 | 9.525 |
12:48 ET | 37433 | 9.51 |
12:50 ET | 2762 | 9.515 |
12:52 ET | 35410 | 9.5 |
12:54 ET | 71180 | 9.415 |
12:56 ET | 29027 | 9.485 |
12:57 ET | 129302 | 9.505 |
12:59 ET | 30581 | 9.495 |
01:01 ET | 18441 | 9.53 |
01:03 ET | 26293 | 9.495 |
01:06 ET | 24603 | 9.445 |
01:08 ET | 21436 | 9.505 |
01:10 ET | 8152 | 9.5 |
01:12 ET | 27729 | 9.495 |
01:14 ET | 6174 | 9.495 |
01:15 ET | 19419 | 9.515 |
01:17 ET | 24018 | 9.48 |
01:19 ET | 131357 | 9.4507 |
01:21 ET | 128101 | 9.4493 |
01:24 ET | 26972 | 9.485 |
01:26 ET | 56224 | 9.415 |
01:28 ET | 32691 | 9.45 |
01:30 ET | 8562 | 9.445 |
01:32 ET | 7412 | 9.445 |
01:33 ET | 30849 | 9.425 |
01:35 ET | 20496 | 9.3901 |
01:37 ET | 64897 | 9.335 |
01:39 ET | 53103 | 9.35 |
01:42 ET | 39251 | 9.39 |
01:44 ET | 328108 | 9.395 |
01:46 ET | 15402 | 9.365 |
01:48 ET | 6979 | 9.37 |
01:50 ET | 92123 | 9.41 |
01:51 ET | 27000 | 9.3888 |
01:53 ET | 16139 | 9.4194 |
01:55 ET | 9539 | 9.385 |
01:57 ET | 14953 | 9.4 |
02:00 ET | 12932 | 9.4 |
02:02 ET | 8588 | 9.455 |
02:04 ET | 38564 | 9.455 |
02:06 ET | 15581 | 9.4 |
02:08 ET | 17304 | 9.405 |
02:09 ET | 3539 | 9.445 |
02:11 ET | 10118 | 9.415 |
02:13 ET | 6743 | 9.4075 |
02:15 ET | 23079 | 9.46 |
02:18 ET | 9593 | 9.465 |
02:20 ET | 10146 | 9.44 |
02:22 ET | 26481 | 9.435 |
02:24 ET | 17174 | 9.401 |
02:26 ET | 28682 | 9.395 |
02:27 ET | 23747 | 9.395 |
02:29 ET | 60788 | 9.4 |
02:31 ET | 16771 | 9.4312 |
02:33 ET | 12293 | 9.41 |
02:36 ET | 3992 | 9.425 |
02:38 ET | 21256 | 9.465 |
02:40 ET | 29496 | 9.495 |
02:42 ET | 44164 | 9.465 |
02:44 ET | 25623 | 9.49 |
02:45 ET | 32206 | 9.405 |
02:47 ET | 12686 | 9.425 |
02:49 ET | 9432 | 9.456 |
02:51 ET | 15597 | 9.43 |
02:54 ET | 17073 | 9.415 |
02:56 ET | 124349 | 9.38 |
02:58 ET | 46945 | 9.415 |
03:00 ET | 20026 | 9.41 |
03:02 ET | 20012 | 9.405 |
03:03 ET | 58776 | 9.4007 |
03:05 ET | 35458 | 9.4 |
03:07 ET | 74541 | 9.39 |
03:09 ET | 25250 | 9.3388 |
03:12 ET | 102796 | 9.3 |
03:14 ET | 127855 | 9.25 |
03:16 ET | 59680 | 9.255 |
03:18 ET | 155725 | 9.11 |
03:20 ET | 63846 | 9.1301 |
03:21 ET | 51095 | 9.1638 |
03:23 ET | 54081 | 9.115 |
03:25 ET | 75656 | 9.145 |
03:27 ET | 93654 | 9.115 |
03:30 ET | 9322 | 9.115 |
03:32 ET | 143319 | 9.105 |
03:34 ET | 218654 | 9.15 |
03:36 ET | 158483 | 9.075 |
03:38 ET | 52196 | 9.095 |
03:39 ET | 184866 | 8.995 |
03:41 ET | 120403 | 9.01 |
03:43 ET | 489397 | 9.005 |
03:45 ET | 94138 | 8.995 |
03:48 ET | 75696 | 9.005 |
03:50 ET | 188167 | 8.755 |
03:52 ET | 211233 | 8.72 |
03:54 ET | 122424 | 8.745 |
03:56 ET | 96907 | 8.84 |
03:57 ET | 158508 | 8.835 |
03:59 ET | 780879 | 8.84 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 6.1B | -53.4x | --- |
Revolution Medicines Inc | 6.3B | -10.7x | --- |
Cytokinetics Inc | 5.6B | -9.2x | --- |
Viking Therapeutics Inc | 6.9B | -66.9x | --- |
BridgeBio Pharma Inc | 5.2B | -9.0x | --- |
Madrigal Pharmaceuticals Inc | 5.0B | -10.6x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.03 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -53.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.